CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The 2nd Generation Malaria Vaccine Consortium aims to advance the development of a new malaria vaccine targeting Plasmodium falciparum. This project focuses on clinical trials to ensure safety and efficacy in African infants while fostering local scientific expertise.
The 2nd Generation Malaria Vaccine Consortium (MVC-2G) will build on the programmatic use of the first-generation Plasmodium falciparum vaccine, R21 with Matrix-M™, and accelerate the clinical development of the leading second-generation multi-stage P. falciparum malaria vaccine comprising R21 and two novel blood-stage components, RH5.1 and R78C, all formulated in Matrix-M™.
It will achieve this through a multi-disciplinary workplan, underpinned by international cooperation, that will accelerate…
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Burkina Faso, Ouagadougou
Type: Research institute
Activity type: Research Organisations
SME: No
Sierra Leone, FREETOWN
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Senegal, Dakar
Type: Research institute
Activity type: Research Organisations
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
